Total Payments
$10,973
2024 Payments
$2,171
Companies
43
Transactions
606
Medicare Patients
3,701
Medicare Billing
$433,690
Payment Breakdown by Category
Food & Beverage$10,904 (99.4%)
Education$69.00 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,904 | 605 | 99.4% |
| Education | $69.00 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,144 | 168 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,468 | 81 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,152 | 66 | $0 (2024) |
| Gilead Sciences, Inc. | $872.59 | 46 | $0 (2024) |
| PFIZER INC. | $507.88 | 31 | $0 (2024) |
| Janssen Biotech, Inc. | $428.75 | 27 | $0 (2024) |
| Celgene Corporation | $413.94 | 29 | $0 (2024) |
| QOL Medical, LLC | $337.52 | 17 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $293.56 | 17 | $0 (2024) |
| GENZYME CORPORATION | $210.64 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,171 | 113 | ABBVIE INC. ($392.24) |
| 2023 | $1,501 | 90 | ABBVIE INC. ($362.54) |
| 2022 | $1,147 | 63 | ABBVIE INC. ($382.74) |
| 2021 | $1,808 | 94 | AbbVie Inc. ($757.85) |
| 2020 | $1,083 | 57 | AbbVie Inc. ($496.84) |
| 2019 | $1,638 | 86 | AbbVie, Inc. ($355.72) |
| 2018 | $1,024 | 66 | AbbVie, Inc. ($340.41) |
| 2017 | $601.96 | 37 | Valeant Pharmaceuticals North America LLC ($81.71) |
All Payment Transactions
606 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Gastroenterology | ||||||
| 12/17/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $9.83 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.54 | General |
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2024 | Echosens North America, Inc. | FibroScan (Device) | Food and Beverage | Cash or cash equivalent | $34.45 | General |
| Category: Elastography | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $6.03 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Gastroenterology | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.21 | General |
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Gastroenterology | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Gastroenterology | ||||||
| 11/18/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $15.44 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/13/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Immunology | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/29/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.39 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/24/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,149 | 1,502 | $528,365 | $137,307 |
| 2022 | 17 | 1,148 | 1,543 | $507,417 | $130,620 |
| 2021 | 15 | 690 | 764 | $369,742 | $84,689 |
| 2020 | 12 | 714 | 749 | $354,602 | $81,074 |
Total Patients
3,701
Total Services
4,558
Medicare Billing
$433,690
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 163 | 165 | $162,690 | $31,441 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 223 | 252 | $48,636 | $23,993 | 49.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 79 | 80 | $57,760 | $14,324 | 24.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 154 | 322 | $24,950 | $9,680 | 38.8% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 68 | 156 | $17,608 | $9,231 | 52.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 106 | 109 | $69,651 | $8,578 | 12.3% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 57 | 112 | $17,296 | $8,170 | 47.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 30 | 31 | $22,398 | $5,414 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 40 | $10,400 | $5,208 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 63 | $8,127 | $4,243 | 52.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 33 | 33 | $28,859 | $3,737 | 12.9% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 31 | 31 | $17,980 | $3,714 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $7,992 | $2,959 | 37.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 33 | 34 | $18,700 | $2,881 | 15.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $11,688 | $2,103 | 18.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 20 | $1,530 | $866.31 | 56.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,101 | $765.55 | 36.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 180 | 181 | $178,466 | $34,126 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 187 | 210 | $40,530 | $20,943 | 51.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 229 | 446 | $39,633 | $12,891 | 32.5% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2022 | 76 | 176 | $19,768 | $10,154 | 51.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 47 | 48 | $34,656 | $8,710 | 25.1% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2022 | 62 | 112 | $17,160 | $8,194 | 47.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 96 | 96 | $61,344 | $6,959 | 11.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $11,840 | $4,818 | 40.7% |
About Dr. Kendell Mann, MD
Dr. Kendell Mann, MD is a Gastroenterology healthcare provider based in Fort Carson, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053384347.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kendell Mann, MD has received a total of $10,973 in payments from pharmaceutical and medical device companies, with $2,171 received in 2024. These payments were reported across 606 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($10,904).
As a Medicare-enrolled provider, Mann has provided services to 3,701 Medicare beneficiaries, totaling 4,558 services with total Medicare billing of $433,690. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Fort Carson, CO
- Active Since 02/08/2006
- Last Updated 11/13/2013
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1053384347
Products in Payments
- HUMIRA (Biological) $1,113
- XIFAXAN (Drug) $1,029
- Humira (Biological) $726.34
- RINVOQ (Biological) $533.27
- Entyvio (Biological) $457.86
- XELJANZ (Drug) $452.58
- ENTYVIO (Biological) $451.06
- ZEPOSIA (Drug) $413.94
- STELARA (Biological) $352.37
- DUPIXENT (Biological) $321.59
- LINZESS (Drug) $287.20
- Linzess (Drug) $267.82
- TRULANCE (Drug) $267.53
- CREON (Drug) $238.46
- OCALIVA (Drug) $192.73
- SUCRAID (Drug) $184.17
- SKYRIZI (Biological) $168.25
- INJECTAFER (Drug) $166.59
- OMVOH (Drug) $165.67
- Sucraid (Drug) $153.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.